Patient Worthy

LISTEN TO OUR PODCAST

THE LATEST FROM PATIENT WORTHY

Cancer

Myth Buster: You Don’t Need a High Protein Diet

Editor’s Note: Patient Worthy is honored to share this article from our friend Julie Lanford, MPH, RD, CSO, LDN – a.k.a. The Cancer Dietitian. To

Chronic Lymphocytic Leukemia

The Weight of Thank You

Editor’s Note: Patient Worthy is honored to share the following story from our friends at Elephants & Tea, originally written by Michelle Lawrence, a patient

Dementia

Muscle Loss May Be More Closely Linked to Dementia Risk Than Body Weight, Review Finds

As reported on SciTechDaily, a large research review suggests age-related losses in muscle mass, strength, and physical function may have a stronger association with dementia

IgA Nephropathy (IgAN)

Phase 3 IMAgINATION Trial of Sefaxersen Meets Primary Endpoint in IgA Nephropathy

Investigational once-monthly therapy significantly reduced proteinuria versus placebo at 37 weeks, according to interim findings from the phase 3 study. As reported on PharmaBiz, Roche

Brain Cancer

Perpetually Healing

Editor’s Note: Patient Worthy is proud to share the following story from our friends at Elephants & Tea, originally written by Dillon Groover, a brain

Microvillus Inclusion Disease

One Mom’s Fight to Change the Language Around Microvillus Inclusion Disease (MVID)

Editor’s Note: Patient Worthy is honored to share this article from our friends at Rareative. To see the article in its original format, please click

Muscle invasive bladder cancer

FDA Grants Priority Review to Imfinzi-Enfortumab Vedotin Regimen for Muscle-Invasive Bladder Cancer

As reported on PharmaBiz, the FDA has accepted AstraZeneca’s supplemental Biologics License Application for durvalumab plus neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cancer

Myelofibrosis

Selcodebart Shows Hematologic Activity in Myelofibrosis-Associated Anemia

As reported on ONC Live, early findings from the phase 1/2 RALLY-MF trial suggest selcodebart may improve hemoglobin levels and reduce dependence on red blood

Dengue Fever

Dengue Fever: If Half the World Is at Risk, Why Has No One Prevented It?

Once concentrated largely in tropical and subtropical regions, dengue is posing an expanding public health challenge as climate conditions, urbanization and population movement increase the

Diabetic retinopathy

Investigational Drug Could Help Against Diabetic Retinopathy

Diabetic retinopathy affects approximately 30% of adults with diabetes and stands as one of the leading causes of vision loss among working-age individuals worldwide. The

Diffuse Large B-cell Lymphoma

Barb’s Fight Against Stage 4 Lymphoma

In June 2024, I went to the emergency room because the “flu” I’d been diagnosed with a week earlier had turned into abdominal pain that

Lung Cancer

Rare Inherited EGFR Mutation Greatly Raises Lung Cancer Risk

People who inherit a rare change in the EGFR gene may be much more likely to develop lung cancer. Their risk is about 25 times

Metabolic dysfunction-associated steatohepatitis

Singapore Approves Wegovy for MASH With Moderate to Advanced Liver Fibrosis

Semaglutide 2.4 mg becomes Singapore’s first approved therapy for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis. As reported on the Manila Times, Singapore’s

Ebola

Ebola – Lessons Learned

The Ebola Outbreak: DR Congo The Ebola outbreak in DR Congo was declared in May 2026. As reported by the BBC, it is now the

Rare Disease

Synapticure: A Nationwide Neurology Network Developed by Utilizing Telehealth

Patients in the United States wait an average of 34 to 50 days (roughly 1 to 1.5 months) for an initial neurology appointment, with wait

Renal Cell Carcinoma

FDA Expands Welireg Use in Kidney Cancer With Lenvima Combination

As reported on FiercePharma, Merck & Co.’s Welireg has secured an expanded FDA approval that moves the drug earlier in the treatment of advanced kidney